Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of de-escalation strategies in early breast cancer
2026-527524-27-00Phase 2Authorised
- Sponsor
- INOC - Istituto Nazionale Oncologico Candiolo
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib, tamoxifen, capecitabine, exemestane, letrozole and 11 more in breast cancer (2 arms), sponsored by INOC - Istituto Nazionale Oncologico Candiolo. Planned start Sep 2026; status: authorised.
02
Drugs
ribociclibtamoxifencapecitabineexemestaneletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2026-527524-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527524-27-00.